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The diagnosis of familial defective apolipoprotein B-100 (FDB) has been facilitated by the use of mutagenic polymerase chain reaction (PCR) primers to introduce restriction sites at the FDB gene locus. We describe a two-test strategy for diagnosing FDB that overcomes the potential for error in single-test methods based on such techniques. We introduce an Sau961 restriction site for PCR products of the normal apolipoprotein B allele. Incomplete digestion of the PCR product with Sau961 suggests an FDB heterozygote, although a false-positive result due to nonideal digestion conditions remains a possibility. in such cases we use a second test that introduces an ScaI restriction site in PCR productsof the FDB allele. The diagnosis is confirmed if half of this product can be digested with Scal 
Materials and Methods
Re8ults
The principle of introducing restriction sites at the FDB locus by using PCR is illustrated in Figure 1 and 0.5 g of bovine serum albumin per liter).
Using the methods described, we identified two unrelated cases of FDB. We screened 60 patients presenting with type ha hyperlipoproteinemia, including FH, at our lipid clinic, and we detected one FDB heterozygote. to confirm a theoretical advantage. Nevertheless, both our tests appear robust with little sensitivity to moderate changes in magnesium ion concentration and annealing temperatare, important determinants of PCR product yield and specificity that often need to be precisely controlled (14) . We have, however, observed an effect that is a potential source of error in assays of this type: in introducing an Sea! site for the FDB allele, we found that the extent to which the PCR product could be digested to smaller fragments with Sea! decreased at annealing temperatures >52 #{176}C, with very little being digested at annealing temperatures of 61 #{176}C. Therefore, selective amplification of the normal alleles may occur at higher annealing temperatures, perhaps because the first base pair formed upon extension of the GLN primer by Taq pelymerase is GC (three hydrogen bonds) when the normal allele is the template, compared with AT (two hydrogen bonds) for an FDB allele. The potential for errors in methods based on such techniques can be avoided if the method for amplification of both alleles is optimized. No such effect was observed for the B1/ARG primer pairs, possibly because the ARG primer contained only one mismatch compared with two for the GLN primer.
Our method is economical. The PCR reactions use only 0.25 U of Taq pelymerase; for the screening test, digestion requires only 0.5 U of Sau96!. The amount of Sea! used for the confirmatory test (24 U) is considerable. However, we do not consider this to be a problem because the confirmatory test is used only when the screening test suggests an FDB heterozygote. Alternatively, much less Sea! (1 U) can be used if the PCR product is purified by ethanol precipitation before digestion.
Using these methods, we have detected two cases of FDB, bringing to four the total number of index cases described in Australia (15) . Both our cases were detected from screening of patients presenting with a type ila hyperlipoproteinemia.
In conclusion, we have developed a two-test strategy for diagnosing FDB based on the use of mutagenic PCR primers to introduce restriction sites at the FDB locus. This approach overcomes the potential for error in single-test methods based on the same principles. The two tests used in our method are robust regarding important determinants of PCR product yield and specificity. We used the method for diagnosing two unrelated cases of FDB.
